Your session is about to expire
← Back to Search
Pembrolizumab + CRT for Head and Neck Cancer
Study Summary
This trial is testing a new combination of drugs to treat head and neck cancer. The new combination consists of pembrolizumab, a standard chemotherapy drug, and cisplatin, a radiation therapy. Patients will not be randomized, and all will receive the new combination.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2012 Phase 3 trial • 256 Patients • NCT01005680Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have or had lung inflammation not caused by an infection.I have been treated for an autoimmune disease in the last 2 years.My cancer is a type of throat or mouth cancer, not including the lip.I am willing to give a tissue sample from a recent biopsy.My cancer is at an advanced stage (stage III, IVA, or IVB).I am not pregnant and agree to use birth control.I have had radiation therapy to my head or neck.My cancer has spread to distant parts of my body.I have an active tuberculosis infection.I haven't taken any experimental drugs or cancer treatments in the last 4 weeks.I have previously received specific anti-cancer treatments.I have cancer that has spread to my brain or spinal cord.You have a disease that can be measured using a specific set of guidelines.I have not taken steroids or immunosuppressants in the last 7 days.I agree to use birth control during the study.I am currently on medication for an infection.I don't have any health issues that could affect the trial's results.I have previously been treated with specific medications.I have a history of HIV or active Hepatitis B or C.I have not received a live vaccine in the last 30 days.I am fully active or restricted in physically strenuous activity but can do light work.My organs are functioning well.I have another cancer that is getting worse or needs treatment.I am at least 18 years old.You are allergic to pembrolizumab or any of its ingredients.I am a candidate for treatment aimed at curing my cancer using both chemotherapy and radiation at the same time.
- Group 1: Single Arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any published accounts detailing Cisplatin's efficacy in the medical field?
"The City of Hope Comprehensive Cancer Center initially began researching cisplatin in 1997, with 1214 trials having been completed since then. At present, 1555 live clinical studies are being conducted across the country, many of which originate from Fargo, North dakota."
Are there any available enrollment slots for this clinical experiment?
"This research is no longer recruiting participants. According to the clinicaltrials.gov records, recruitment first began on November 1st 2015 and concluded in April 19th 2022. Alternatives are available; 2911 studies for oropharynx cancer patients and 1555 trials involving Cisplatin treatment are currently accepting enrollees."
In what context is Cisplatin typically administered?
"Cisplatin has been shown to be an effective treatment for malignant tumours, inoperable melanomas, and microsatellite instability high conditions."
How many research centers are carrying out this trial?
"The list of medical centres involved in this trial includes Sanford-Roger Maris Cancer Center (Fargo), the Sanford Health Centre (Sioux Falls) and the Sanford-Bismarck Medical Facility, plus other 4 sites."
How many individuals are partaking in this clinical experiment?
"Recruitment for this research has closed. The trial was posted on November 1st, 2015 and last updated April 19th 2022. For those seeking to join other trials, 2911 are recruiting patients with oropharynx cancers and 1555 studies have open enrollment for cisplatin treatments."
What are the potential risks associated with Cisplatin treatment?
"The safety of Cisplatin was estimated to be 1 on a scale from 1-3 due to the fact that this is only its initial stage of clinical trials and there is limited data supporting both efficacy and safety."
Share this study with friends
Copy Link
Messenger